Skip to main content
Program for Advanced Cell Therapy
Integrated personalized cell technologies for improving health outcomes in children and adults
  • HOME
  • ABOUT US Expand Collapse
    • FROM THE DIRECTOR
    • OUR SERVICES
    • OUR TEAM
    • OUR FACILITY
  • CLINICAL TRIALS
  • EDUCATION
  • PACT ADVISORY BOARD
  • NEWS AND EVENTS
  1. Home
  2. Year: 2022
  3. Month: November

Month: November 2022

UW Program for Advanced Cell Therapy Director of R&D secures membership to UW Carbone Cancer Center

Posted on November 22, 2022

On November 16 2022, Andrea Pennati secured associate membership within the UW Carbone Cancer Center in the UW School of Medicine and Public Health. He has been appointed as a member of the UWCCC’s Developmental Therapeutics Program where innovations in …

Posted in Uncategorized

PACT Intern Completes MS in Applied Drug Development – joins manufacturing team

Posted on November 16, 2022

Xingyi Tang completed her Master of Science in the University of Wisconsin-Madison, School of Pharmacy Applied Drug Development program. Ms. Tang chose to complete the internship portion of her requirements in the UW Program for Advanced Cell Therapy. …

Posted in Uncategorized

Pilot Study of autologous MSCs for Radiation-Induced Xerostomia (Dry Mouth) in Head and Neck Cancer Patients Completed

Posted on November 13, 2022

The UW Program for Advanced Cell Therapy has completed enrollment for the pilot MARSH (Marrow-derived Autologous Stromal cells for the Restauration of Salivary Hypofunction) clinical trial. Six patients with radiation-induced Xerostomia (Dry Mouth) were treated in the …

Posted in Uncategorized

PACT Adds New Member to the cGMP Manufacturing Team!

Posted on November 13, 2022

The UW Program for Advanced Cell Therapy welcomes Jessica Murphy, BS, MLS (ASCP) as our new Process Development and Manufacturing Scientist. Ms. Murphy comes to us from the Center for Regenerative Medicine; Immune, Progenitor and Cell Therapy (IMPACT) …

Posted in Uncategorized

UW PACT submits Annual Report to FDA CBER for Viral-Specific Cell therapy IND

Posted on November 13, 2022

The Annual Report for the IND covering a University of Wisconsin (UW) clinical trial evaluating the safety of donor Viral-Specific T cells against CMV (cytomegalovirus) infection was submitted to the FDA CBER this week. This …

Posted in Uncategorized

Site footer content

University logo that links to main university website

Contact Us

  • 1111 Highland Ave
    WIMR - Third Floor
    Madison, WI 53705
  • Email: caweinberger@wisc.edu
  • Phone: 608-263-0078

Website feedback, questions or accessibility issues: caweinberger@wisc.edu.

This site was built using the UW Theme. © 2023 Board of Regents of the University of Wisconsin System. | Privacy Notice